We maximize the impact of every clinical trial by studying samples in the lab. For example, using blood samples collected in the VERTU trial, we are developing a simple blood test based on cell-free DNA (cfDNA) methylation, a non-invasive way to detect brain tumors and monitor treatment response without surgery. By leveraging epigenetic signatures found in cfDNA and conducting longitudinal molecular profiling in individuals with aggressive, currently incurable tumors, the study seeks to enhance risk stratification, optimize clinical trial design, and strengthen disease surveillance, ultimately accelerating therapeutic development.
Box and whisker plot showing the heightened methylation risk for glioblastoma patients as compared to healthy individuals